псилоцибин作为变革性的快速起作用抗抑郁药:药理性质和分子机制
Makiath Adebo1, Mathilda Bonnet1, Ons Laouej1
1Université Paris-Saclay, Inserm CESP/UMR 1018, MOODS Team, Orsay, France.
Fundamental & clinical pharmacology
|July 16, 2025
概括
一种迷幻化合物psilocybin在治疗抑郁症方面表现有前途. 研究正在探索其机制,重点关注血清素受体和神经可塑性,以了解其抗抑郁药的潜力.
科学领域:
- 神经科学是一个神经科学.
- 心理药理学 心理药理学
- 心理健康研究 心理健康研究
背景情况:
- 在20世纪中叶,用于治疗成的血清催化剂被探索.
- 几十年来,由于法律限制和对精神活性效应的担忧,迷幻药的研究停止了.
- 最近的临床试验表明,在治疗耐药抑郁症中,迷幻药,特别是 псилоцибин具有治疗潜力.
研究的目的:
- 审查关于 псилоцибин及其代谢物psilocin的临床试验和临床前研究.
- 阐明潜素潜在抗抑郁作用背后的作用机制.
- 更新关于血清素5-HT2A受体激素在西宾治疗作用中的作用.
主要方法:
- 对涉及西治疗抑郁症的开创性临床试验的审查.
- 对psilocybin和psilocin的药理学进行临床前研究的分析.
- 对神经递质系统,神经可塑性和神经回路受到psilocin影响的研究进行审查.
主要成果:
- псилоцибин和 псилоцин主要作为血清素5-HT2A受体激活剂.
- 5-HT2A受体激活与迷幻效应有关,但其在抗抑郁药作用中的作用仍在争论中.
- 西洛辛会影响各种神经递质系统,神经可塑性和与情绪调节相关的神经回路.
结论:
- 了解psilocybin的抗抑郁机制对于开发新型抑郁症治疗至关重要.
- 需要进一步的研究来验证psilocybin的治疗潜力,可能与常规抗抑郁药一起使用.
- 迷幻药研究的复兴凸显了它们在解决全球日益增长的抑郁症负担方面的潜力.
更多相关视频
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
184
07:30HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
Published on: July 9, 2016
7.4K
相关概念视频
CNS Stimulants: Psychedelic Agents
252
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
252
Antidepressant Drugs: MAOIs and Other Agents
372
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
372
Hallucinogens and Psychedelics
287
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
287
Antidepressant Drugs: Overview
777
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
777
Drug Therapy
105
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
105
Psychosis: Goals of Pharmacotherapy
212
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
212
